Literature DB >> 18622671

Antimicrobial susceptibility and molecular epidemiological analysis of clinical strains of Pseudomonas aeruginosa.

Noriko Tsuchimochi1, Takahiro Takuma, Nobuyuki Shimono, Yoji Nagasaki, Yujiro Uchida, Mine Harada.   

Abstract

Three hundred and seventy-one strains of Pseudomonas aeruginosa were isolated at the laboratory of Kyushu University Hospital in Japan from May 2002 through January 2003. Large proportions of isolated strains were resistant to carbapenems: 37.5% to imipenem, 21.3% to biapenem, and 18.3% to meropenem. A survey of injectable antibacterial agents used in our hospital during the corresponding period showed that carbapenems were most frequently used. Multidrug-resistant P. aeruginosa (MDRP) strains and metallo-beta-lactamase producing strains were isolated at frequencies of 1.6% (6 strains) and 0.81% (3 strains), respectively. By molecular epidemiological analysis, neither MDRP nor metallo-beta-lactamase producing strains were molecularly related, whereas some imipenem-resistant strains appeared to be epidemic strains, suggesting a possibility that they might spread by nosocomial infection. To control nosocomial infection, it is important to know a trend in drug-resistant P. aeruginosa and to prevent the spread of not only MDRP and metallo-beta-lactamase producing strains but also imipenem-resistant P. aeruginosa strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622671     DOI: 10.1007/s10156-007-0578-8

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  3 in total

1.  Interplay between mutational and horizontally acquired resistance mechanisms and its association with carbapenem resistance amongst extensively drug-resistant Pseudomonas aeruginosa (XDR-PA).

Authors:  Jwu-Ching Shu; Ju-Hsin Chia; Leung-Kei Siu; An-Jing Kuo; Shu-Huan Huang; Lin-Hui Su; Tsu-Lan Wu
Journal:  Int J Antimicrob Agents       Date:  2011-11-10       Impact factor: 5.283

2.  Biapenem versus meropenem in the treatment of bacterial infections: a multicenter, randomized, controlled clinical trial.

Authors:  Xiaohui Wang; Xiaoke Zhang; Zhiyong Zong; Rujia Yu; Xiaoju Lv; Jianbao Xin; Chaohui Tong; Qinglin Hao; Zhiqiang Qin; Ying Xiong; Hong Liu; Guohua Ding; Chengping Hu
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

3.  Berberine Is a Novel Type Efflux Inhibitor Which Attenuates the MexXY-Mediated Aminoglycoside Resistance in Pseudomonas aeruginosa.

Authors:  Yuji Morita; Ken-Ichi Nakashima; Kunihiko Nishino; Kenta Kotani; Junko Tomida; Makoto Inoue; Yoshiaki Kawamura
Journal:  Front Microbiol       Date:  2016-08-05       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.